Glycomed, Inc.

University of Florida Research Foundation Inc

Daniel E Levy

Peng Cho Tang

John H Musser

Kevin R Holme

Gregory Scott Schultz

Mark Brian Anderson

Narasinga Rao

Richard E Galardy

Damian Grobelny

Saeed A Abbas

Cho Tang

Asaad Nematalia

Falguni Dasgupta

Jing Rong Cui

Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.

Process for preparing synthetic matrix metalloprotease inhibitors

Compounds that possess selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or their mimics are separated by a linker that permits binding between those groups and the selecting, such compounds being represented by the following general structural formula I: ##STR1##

Sialyl lewis-x mimetics containing naphthyl backbones

Sialyl Lewis.sup.x mimetics containing phenyl backbones

Synthetic matrix metalloprotease inhibitors and use thereof

Compounds that exhibit selectin binding activity are described and have the following structural formula: ##STR1## where W is selected from a group including structures a-d below ##STR2## wherein p is an integer of from 0-2, q is an integer of from 0-3, and r is an integer of from 0-5;

Sialic acid/fucose based medicaments

Glyco-amino acids and glycopeptides having three-dimensionally stable configurations are described. These glyco-amino acids and glycopeptides have glycoside functional groups, such as fucose and analogues and derivatives thereof, covalently bound to an amino acid or peptide having a free carboxylic group or sulfate group in an orientation that facilitates the binding between these groups and selectin receptors. The present glyco-amino acids and glycopeptides may be used in the treatment of selectin-mediated disorders, such as inflammation, autoimmune disease and cancer.

Selectin binding glycopeptides

Glyco-amino acids or glycopeptides that have three-dimensionally stable configuration for the presentation of functional groups, fucose, or an analogue or derivative thereof, covalently linked to an amino acid or peptide with a free carboxylic acid group, that facilitate binding between those groups and receptors on selectins, represented by the general structural formula I.

Growing community of inventors

Alameda, CA, United States of America

Daniel E Levy